(19)
(11) EP 2 906 684 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.09.2020 Bulletin 2020/36

(45) Mention of the grant of the patent:
22.07.2020 Bulletin 2020/30

(21) Application number: 13845951.6

(22) Date of filing: 10.10.2013
(51) International Patent Classification (IPC): 
C12N 5/0783(2010.01)
C12N 15/87(2006.01)
C07K 16/28(2006.01)
C12N 15/00(2006.01)
A61K 35/17(2015.01)
(86) International application number:
PCT/US2013/064384
(87) International publication number:
WO 2014/059173 (17.04.2014 Gazette 2014/16)

(54)

T CELL MODIFYING COMPOUNDS AND USES THEREOF

T-ZELL-MODIFIZIERENDE VERBINDUNGEN UND VERWENDUNGEN DAVON

COMPOSÉS MODIFIANT LES LYMPHOCYTES T ET LEURS UTILISATIONS


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 10.10.2012 US 201261712028 P

(43) Date of publication of application:
19.08.2015 Bulletin 2015/34

(60) Divisional application:
20183942.0

(73) Proprietor: Sangamo Therapeutics, Inc.
Brisbane, CA 94005 (US)

(72) Inventors:
  • GREGORY, Philip D.
    Richmond California 94804 (US)
  • HOLMES, Michael C.
    Richmond California 94804 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
WO-A2-2008/153742
US-A1- 2011 158 957
US-A1- 2011 158 957
   
  • BERGER C ET AL: "Adoptive transfer of virus-specific and tumor-specific T cell immunity", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 21, no. 2, 1 April 2009 (2009-04-01), pages 224-232, XP026058400, ISSN: 0952-7915, DOI: 10.1016/J.COI.2009.02.010 [retrieved on 2009-03-21]
  • H. TORIKAI ET AL: "A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR", BLOOD, vol. 119, no. 24, 14 June 2012 (2012-06-14), pages 5697-5705, XP055071623, ISSN: 0006-4971, DOI: 10.1182/blood-2012-01-405365
  • PADMANEE SHARMA ET AL: "Novel cancer immunotherapy agents with survival benefit: recent successes and next steps", NATURE REVIEWS CANCER, vol. 11, no. 11, 24 October 2011 (2011-10-24), pages 805-812, XP055110127, ISSN: 1474-175X, DOI: 10.1038/nrc3153
  • KALOS MICHAEL ET AL: "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", 20110810, vol. 3, no. 95, 10 August 2011 (2011-08-10), page 95ra73.1, XP002667262,
  • DREW M. PARDOLL: "The blockade of immune checkpoints in cancer immunotherapy", NATURE REVIEWS CANCER, vol. 12, no. 4, 22 March 2012 (2012-03-22) , pages 252-264, XP055150744, ISSN: 1474-175X, DOI: 10.1038/nrc3239
  • BERGER ET AL.: 'Adoptive transfer of virus-specific and tumor-specific T cell immunity' CURR OPIN IMMUNOL. vol. 21, no. 2, April 2009, pages 224 - 232, XP026058400
  • TORIKAI ET AL.: 'A foundation for universal T- cell based immunotherapy: T cells engineered to express a CD 19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR' BLOOD vol. 119, no. 24, 14 June 2012, pages 5697 - 5705, XP055071623
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).